Denali Therapeutics Inc(NASDAQ:DNLI) 
Denali Therapeutics Inc., a biopharmaceutical company, discovers and develops therapeutic candidates for neurodegenerative diseases in the United States. The company offers leucine-rich repeat kinase 2 (LRRK2) inhibitor product candidates, including DNL201 that has completed Phase 1b clinical trials...
Website: http://www.denalitherapeutics.com
Founded: 2013
Full Time Employees: 281
Sector: Healthcare
Industry: Biotechnology
The information provided in this report is taken from www.sec.gov. While we have conducted our best efforts to ensure that the parsed data is accurate, we cannot guarantee its accuracy. Please use caution and understand that any consequences of its use are your own responsibility.
Day
Week
Month
Date 2025-04-04
P
O 12.32
H 12.63
L 11.35
C 11.78
V 1,529,150
10EMA 11.78
20EMA 11.78
60EMA 11.78
120EMA 11.78
250EMA 11.78